Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the stock has risen by around just 3%. This is not the type of investment ...

Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...

Read here for an update on Yacktman Asset Management's portfolio changes, top holdings, and performance compared to market ...

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...

Dividend stocks attract income-focused investors due to their consistent and dependable payouts. However, not all dividend stocks offer the same benefits. A select group of companies, known as ...

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

Johnson & Johnson (NYSE:JNJ) researches, develops, manufactures and sells various products in the health care field worldwide ...

Johnson & Johnson (JNJ) stock saw a modest uptick, ending the day at $152.89 which represents a slight increase of $6.07 or 4.13% from the prior close of $146.82. The stock opened at $ and touched a ...

HistoSonics Inc., a medical device company whose backers include Johnson & Johnson’s venture capital arm, is weighing a US ...

Holdout creditors who claim tainted baby powder gave them ovarian cancer urged a judge to reject Johnson & Johnson’s plan to ...

With the stock market overbought and insiders selling, shares of these five outstanding large-cap companies look like just ...

Key stocks in the Dow Jones Industrial Average (DJIA), including McDonald’s, JPMorgan, and Goldman Sachs. Analyze ratings, ...